Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study 17/08/2022 14:54 Buisson et.al.; Clinical Gastroenterology and Hepatology 2023 Aug;21(9):2338-2346 קרא עוד ←
